| 19 0.04 (0.21%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.21 | 1-year : | 25.94 |
| Resists | First : | 19.02 | Second : | 22.21 |
| Pivot price | 18.95 |
|||
| Supports | First : | 17.78 | Second : | 17.01 |
| MAs | MA(5) : | 19 | MA(20) : | 18.89 |
| MA(100) : | 13.69 |
MA(250) : | 14.74 |
|
| MACD | MACD : | 0.5  |
Signal : | 0.7 |
| %K %D | K(14,3) : | 93.1 |
D(3) : | 94 |
| RSI | RSI(14): 75.7 | |||
| 52-week | High : | 21.86 | Low : | 8.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ICPT ] has closed below upper band by 29.4%. Bollinger Bands are 92.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 19.02 - 19.11 | 19.11 - 19.19 |
| Low: | 18.77 - 18.88 | 18.88 - 18.98 |
| Close: | 18.84 - 19.01 | 19.01 - 19.15 |
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Wed, 08 Nov 2023
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept ... - Business Wire
Wed, 11 Oct 2023
Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences - Business Wire
Wed, 11 Oct 2023
Intercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five ... - Yahoo Finance
Wed, 27 Sep 2023
Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar? - Yahoo Finance
Wed, 27 Sep 2023
Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal - Zacks Investment Research
Tue, 26 Sep 2023
Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mln - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 81.3 (%) |
| Shares Short | 10,140 (K) |
| Shares Short P.Month | 9,430 (K) |
| EPS | -1.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.72 |
| Profit Margin | -19.4 % |
| Operating Margin | 1.8 % |
| Return on Assets (ttm) | -7.3 % |
| Return on Equity (ttm) | -64.1 % |
| Qtrly Rev. Growth | 14.3 % |
| Gross Profit (p.s.) | 6.8 |
| Sales Per Share | 7.59 |
| EBITDA (p.s.) | -1.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -17.44 |
| PEG Ratio | 1.7 |
| Price to Book value | 11.04 |
| Price to Sales | 2.5 |
| Price to Cash Flow | -12.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|